Predicting COVID-19 progress with clinical scales.
作者信息
Estrada V, González Del Castillo J
机构信息
Servicio de Medicina Interna/Infecciosas, Instituto de Investigación Sanitaria del Hospital Clínico San Carlos (IdISSC), Madrid, Spain.
Servicio de Urgencias, Instituto de Investigación Sanitaria del Hospital Clínico San Carlos (IdISSC), Madrid, Spain.
出版信息
Rev Clin Esp (Barc). 2022 Jan;222(1):42-43. doi: 10.1016/j.rceng.2021.08.001. Epub 2021 Oct 21.
Abstract
摘要
相似文献
1
Predicting COVID-19 progress with clinical scales.使用临床量表预测新冠病毒病的病情进展
Rev Clin Esp (Barc). 2022 Jan;222(1):42-43. doi: 10.1016/j.rceng.2021.08.001. Epub 2021 Oct 21.
2
Progress in understanding COVID-19: insights from the omics approach.对 COVID-19 的认识进展：组学方法的启示。
Crit Rev Clin Lab Sci. 2021 Jun;58(4):242-252. doi: 10.1080/10408363.2020.1851167. Epub 2020 Dec 29.
3
Anti-SARS-CoV-2 IgG responses are powerful predicting signatures for the outcome of COVID-19 patients.抗 SARS-CoV-2 IgG 反应是 COVID-19 患者结局的有力预测标志物。
J Adv Res. 2021 Nov 26;36:133-145. doi: 10.1016/j.jare.2021.11.014. eCollection 2022 Feb.
4
[Progress in the study of antiviral activity of cepharanthine against SARS-CoV-2].千金藤素抗新型冠状病毒2的抗病毒活性研究进展
Nan Fang Yi Ke Da Xue Xue Bao. 2022 Jun 20;42(6):955-956. doi: 10.12122/j.issn.1673-4254.2022.06.22.
5
[Clinical progress of neutralizing antibodies against SARS-CoV-2].[新型冠状病毒2型中和抗体的临床进展]
Sheng Wu Gong Cheng Xue Bao. 2022 Jun 25;38(6):2061-2068. doi: 10.13345/j.cjb.220118.
6
Population-Based COVID-19 Screening in Mexico: Assessment of Symptoms and Their Weighting in Predicting SARS-CoV-2 Infection.墨西哥基于人群的新冠病毒筛查：症状评估及其在预测新冠病毒感染中的权重
Medicina (Kaunas). 2021 Apr 8;57(4):363. doi: 10.3390/medicina57040363.
7
Cepharanthine: A Promising Old Drug against SARS-CoV-2.盐酸千金藤素：抗击 SARS-CoV-2 的有前途的老药。
Adv Biol (Weinh). 2022 Dec;6(12):e2200148. doi: 10.1002/adbi.202200148. Epub 2022 Jul 1.
8
Why data on frailty and SARS-CoV-2 infection are basic to progress.为什么脆弱性和 SARS-CoV-2 感染的数据对于进展至关重要。
Aging Clin Exp Res. 2021 May;33(5):1429-1432. doi: 10.1007/s40520-021-01846-7. Epub 2021 Apr 2.
9
The research progress of SARS-CoV-2 main protease inhibitors from 2020 to 2022.2020 年至 2022 年 SARS-CoV-2 主蛋白酶抑制剂的研究进展。
Eur J Med Chem. 2023 Sep 5;257:115491. doi: 10.1016/j.ejmech.2023.115491. Epub 2023 May 22.
10
A perspective on SARS-CoV-2 virus-like particles vaccines.SARS-CoV-2 病毒样颗粒疫苗的展望。
Int Immunopharmacol. 2023 Feb;115:109650. doi: 10.1016/j.intimp.2022.109650. Epub 2023 Jan 11.
本文引用的文献
1
[Derivation and validation of a risk score for admission to the Intensive Care Unit in patients with COVID-19].[新型冠状病毒肺炎患者重症监护病房收治风险评分的推导与验证]
Rev Clin Esp. 2022 Jan;222(1):1-12. doi: 10.1016/j.rce.2021.06.003. Epub 2021 Jun 23.
2
Biological markers and follow-up after discharge home of patients with COVID-19 pneumonia.COVID-19 肺炎患者出院后的生物标志物及其随访。
Emergencias. 2021 Jun;33(3):174-180.
3
Tocilizumab in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial.托珠单抗治疗 COVID-19 住院患者的疗效（RECOVERY）：一项随机、对照、开放标签、平台试验。
Lancet. 2021 May 1;397(10285):1637-1645. doi: 10.1016/S0140-6736(21)00676-0.
4
Development and validation of a prediction model for 30-day mortality in hospitalised patients with COVID-19: the COVID-19 SEIMC score.开发和验证一种预测模型，用于预测 COVID-19 住院患者 30 天死亡率：COVID-19 SEIMC 评分。
Thorax. 2021 Sep;76(9):920-929. doi: 10.1136/thoraxjnl-2020-216001. Epub 2021 Feb 25.
5
6
[CURB-65 as a predictor of 30-day mortality in patients hospitalized with COVID-19 in Ecuador: COVID-EC study].[CURB-65作为厄瓜多尔COVID-19住院患者30天死亡率的预测指标：COVID-EC研究]
Rev Clin Esp. 2022 Jan;222(1):37-41. doi: 10.1016/j.rce.2020.10.001. Epub 2020 Oct 22.
7
8
9
COVID-19 Is Distinct From SARS-CoV-2-Negative Community-Acquired Pneumonia.COVID-19 不同于 SARS-CoV-2 阴性社区获得性肺炎。
Front Cell Infect Microbiol. 2020 Jun 16;10:322. doi: 10.3389/fcimb.2020.00322. eCollection 2020.
10
Why COVID-19 Silent Hypoxemia Is Baffling to Physicians.为什么 COVID-19 静默性低氧血症让医生感到困惑。
Am J Respir Crit Care Med. 2020 Aug 1;202(3):356-360. doi: 10.1164/rccm.202006-2157CP.
Zotero 插件